Literature DB >> 30746415

MIBG Myocardial Scintigraphy Identifies Premotor PD/DLB During a Negative DAT Scan Period: Second Report.

Ryuji Sakakibara1, Fuyuki Tateno1, Yosuke Aiba1, Tsuyoshi Ogata1, Masahiko Kishi1, Hitoshi Terada2, Tsutomu Inaoka2, Tomoya Nakatsuka2, Katsuyoshi Matsuoka3.   

Abstract

OBJECTIVES: Neuroimaging markers for Parkinson's disease (PD)/dementia with Lewy bodies (DLB) include dopamine transporter (DAT) scanning and metaiodobenzylguanidine (MIBG) myocardial scintigraphy. It is unknown which marker is useful to identify the premotor phase PD/DLB. We reported four patients who, during a negative DAT scan period, had a positive MIBG result that suggested premotor PD/DLB. Here we report 18 additional patients.
METHODS: This study was a prospective cohort study. The recruiting period was five years; prospective follow-up period, 5.5 ± 3.0 years; and a once a year (minimum) follow-up visit. We recruited 745 referred subjects. The inclusion criteria were having at least one of the following known PD nonmotor features: (1) autonomic: postural hypotension (pure autonomic failure [PAF]), constipation, bladder dysfunction; (2) sleep: REM sleep behavior disorder (RBD); and (3) cognitive: mild cognitive impairment or psychiatric symptoms. Also, the patient had to have undergone both DAT and MIBG tests.
RESULTS: Only 18 patients fulfilled these criteria. Their characteristics were: elderly (mean age 75.5 years), with long histories (onset 61.0 years; duration 14.5 years), and predominately male (14 men, four women). The patients' neurologic diagnoses were constipation/RBD in 10, constipation/RBD/PAF in six, and constipation/PAF in two. During the follow-up period, seven patients developed PD or DLB. An abnormal MIBG result was noted in 94%, and an abnormal DAT result was noted in 56%.
CONCLUSIONS: MIBG has the potential to be a useful marker during the DAT scan negative period to identify premotor PD/DLB, but further studies are needed.

Entities:  

Keywords:  Parkinson's disease; REM sleep behavior disorder; constipation; dopamine transporter scan; metaiodobenzylguanidine myocardial scintigraphy

Year:  2018        PMID: 30746415      PMCID: PMC6335543          DOI: 10.1002/mdc3.12697

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  16 in total

1.  Constipation and metaiodobenzylguanidine myocardial scintigraphy abnormality.

Authors:  Fuyuki Tateno; Ryuji Sakakibara; Masahiko Kishi; Emina Ogawa; Nobuo Takada; Nobuo Hosoe; Yasuo Suzuki; Mao Takahashi; Tomoyuki Uchiyama; Tatsuya Yamamoto
Journal:  J Am Geriatr Soc       Date:  2012-01       Impact factor: 5.562

2.  Pure autonomic failure with altered dopamine transporter imaging.

Authors:  Yaroslau Compta; Maria José Martí; Pilar Paredes; Eduardo Tolosa
Journal:  Arch Neurol       Date:  2006-04

3.  Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic.

Authors:  Fuyuki Tateno; Ryuji Sakakibara; Masahiko Kishi; Emina Ogawa; Hitoshi Terada; Tsuyoshi Ogata; Hiroyuki Haruta
Journal:  Parkinsonism Relat Disord       Date:  2011-02-20       Impact factor: 4.891

Review 4.  MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review.

Authors:  Ryuji Sakakibara; Fuyuki Tateno; Masahiko Kishi; Yohei Tsuyusaki; Hitoshi Terada; Tsutomu Inaoka
Journal:  Parkinsonism Relat Disord       Date:  2013-11-21       Impact factor: 4.891

5.  Pure akinesia with low myocardial metaiodobenzylguanidine uptake.

Authors:  Fuyuki Tateno; Ryuji Sakakibara; Masahiko Kishi; Emina Ogawa
Journal:  Parkinsonism Relat Disord       Date:  2011-03-03       Impact factor: 4.891

6.  Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system.

Authors:  K Wakabayashi; H Takahashi; E Ohama; F Ikuta
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 7.  Bladder and bowel dysfunction in Parkinson's disease.

Authors:  R Sakakibara; T Uchiyama; T Yamanishi; K Shirai; T Hattori
Journal:  J Neural Transm (Vienna)       Date:  2008-03-10       Impact factor: 3.575

Review 8.  SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease.

Authors:  Jan Booij; Remco J J Knol
Journal:  Parkinsonism Relat Disord       Date:  2007       Impact factor: 4.891

9.  Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study.

Authors:  A Minguez-Castellanos; C E Chamorro; F Escamilla-Sevilla; A Ortega-Moreno; A C Rebollo; M Gomez-Rio; A Concha; D G Munoz
Journal:  Neurology       Date:  2007-06-05       Impact factor: 9.910

10.  Idiopathic hyposmia as a preclinical sign of Parkinson's disease.

Authors:  Mirthe M Ponsen; Diederick Stoffers; Jan Booij; Berthe L F van Eck-Smit; Erik Ch Wolters; Henk W Berendse
Journal:  Ann Neurol       Date:  2004-08       Impact factor: 10.422

View more
  12 in total

1.  Gastrointestinal function in dementia with Lewy bodies: a comparison with Parkinson disease.

Authors:  Hirokazu Doi; Ryuji Sakakibara; Masayuki Masuda; Fuyuki Tateno; Yosuke Aiba; Masahiko Kishi; Tomonori Yamanishi; Tatsuya Yamamoto; Katsuyoshi Matsuoka
Journal:  Clin Auton Res       Date:  2019-02-11       Impact factor: 4.435

Review 2.  Gastrointestinal dysfunction in movement disorders.

Authors:  Ryuji Sakakibara
Journal:  Neurol Sci       Date:  2021-02-04       Impact factor: 3.307

3.  Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder.

Authors:  Annette Janzen; David Vadasz; Jan Booij; Markus Luster; Damiano Librizzi; Martin T Henrich; Lars Timmermann; Mahboubeh Habibi; Elisabeth Sittig; Geert Mayer; Fanni Geibl; Wolfgang Oertel
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 4.  Gastrointestinal dysfunction in the synucleinopathies.

Authors:  Kathryn A Chung; Ronald F Pfeiffer
Journal:  Clin Auton Res       Date:  2020-11-27       Impact factor: 4.435

5.  Long-term trends in myocardial sympathetic innervation and function in synucleinopathies.

Authors:  Guillaume Lamotte; Courtney Holmes; Tianxia Wu; David S Goldstein
Journal:  Parkinsonism Relat Disord       Date:  2019-09-16       Impact factor: 4.891

6.  Dopamine transporter imaging versus myocardial MIBG scintigraphy for the diagnosis of prodromal synucleinopathies-and other updates on autonomic research.

Authors:  Mitchell G Miglis; Srikanth Muppidi
Journal:  Clin Auton Res       Date:  2019-03-23       Impact factor: 4.435

Review 7.  Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group.

Authors:  Maria Teresa Pellecchia; Iva Stankovic; Alessandra Fanciulli; Florian Krismer; Wassilios G Meissner; Jose-Alberto Palma; Jalesh N Panicker; Klaus Seppi; Gregor K Wenning
Journal:  Mov Disord Clin Pract       Date:  2020-09-03

8.  Reduced central sympathetic activity in Parkinson's disease.

Authors:  Heidrun H Krämer; Gothje Lautenschläger; Michael de Azevedo; Kathrin Doppler; Anne Schänzer; Christoph Best; Wolfgang H Oertel; Iris Reuter; Claudia Sommer; Frank Birklein
Journal:  Brain Behav       Date:  2019-11-05       Impact factor: 2.708

Review 9.  The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline.

Authors:  Per Borghammer
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 10.  Brain-First versus Gut-First Parkinson's Disease: A Hypothesis.

Authors:  Per Borghammer; Nathalie Van Den Berge
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.